Optimizing EGFR Inhibitor-Based Therapies for GBM
OBJECTIVES:
Primary
- Identify molecular characteristics that predict for overall survival and
progression-free survival of patients treated with erlotinib hydrochloride,
temozolomide, and radiotherapy on clinical trial NCCTG-N0177.
Secondary
- Identify molecular characteristics that predict for overall survival and
progression-free survival of patients treated with gefitinib after radiotherapy on
clinical trial NCCTG-N0074.
OUTLINE: This is a multicenter study.
Tissue samples from patients enrolled on clinical trials NCCTG-N0177 or NCCTG-N0074 are
analyzed by microarray analysis and immunohistochemistry for biological markers predicting
progression-free survival and overall survival. Biological markers include epidermal growth
factor expression, vIII mutant p53 gene, P-AKT, p7056k, S6, 4EBP1, STAT-3, PLC-g, Erk,
ErbB2, ErbB3, ErbB4, platelet-derived growth factor receptor, IGF1R, interleukin-6, FADD,
and MGMT.
PROJECTED ACCRUAL: A total of 120 patients will be accrued for this study.
Observational
N/A
Molecular characteristics that predict for overall survival and progression-free survival
No
Jann N. Sarkaria, MD
Study Chair
Mayo Clinic
Unspecified
CDR0000527337
NCT00897663
November 2006
Name | Location |
---|---|
Mayo Clinic Scottsdale | Scottsdale, Arizona 85259 |
Mayo Clinic - Jacksonville | Jacksonville, Florida 32224 |
Mayo Clinic Cancer Center | Rochester, Minnesota 55905 |
Mercy Medical Center - Sioux City | Sioux City, Iowa 51104 |
Siouxland Hematology-Oncology Associates, LLP | Sioux City, Iowa 51101 |
St. Luke's Regional Medical Center | Sioux City, Iowa 51104 |
Rapid City Regional Hospital | Rapid City, South Dakota 57709 |
Mid Dakota Clinic, PC | Bismarck, North Dakota 58501 |
Medcenter One Hospital Cancer Care Center | Bismarck, North Dakota 58501 |
St. Alexius Medical Center Cancer Center | Bismarck, North Dakota 58502 |